Clozapine: A distinct, poorly understood and under-used molecule

Journal of Psychiatry and Neuroscience

Volumn 35, Issue 3, 2010, Pages 147-149

  Joober, Ridha ^a   Boksa, Patricia ^a  

^a DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HISTAMINE RECEPTOR; NEUROLEPTIC AGENT; NEUROTRANSMITTER;

ANXIETY; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; EDITORIAL; EXPIRATION DATE; FOOD INTAKE; HUMAN; METABOLIC DISORDER; MOOD DISORDER; MORTALITY; PATENT; PATIENT COMPLIANCE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM; WEIGHT GAIN; WELLBEING;

EID: 77953334964     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: 10.1503/jpn.100055     Document Type: Editorial

References (44)

1. Blier P. Do antidepressants really work? J Psychiatry Neurosci 2008; 33:89-90.
2. Marder SR, Van PT. Who should receive clozapine? Arch Gen Psychiatry 1988;45:865-7.
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatmentresistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
4. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58:965-72.
5. Hong CJ, Chen JY, Chiu HJ, et al. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol 1997;12:123-30.
6. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008;63:524-9.
7. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001;158:1305-13.
8. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006;10:iii-xi, 1.
9. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007;30:511-33.
10. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res 2008;100:20-38.
11. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156: 294-8.
12. Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52:1510-4.
13. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a populationbased study in schizophrenia. J Clin Psychiatry 2007;68:818-25.
14. Nasrallah HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 2007;68(Suppl 1):5-11.
15. Ascher-Svanum H, Zhu B, Faries DE, et al. Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia. Patient Prefer Adherence 2008; 2:67-77.
16. Green AI, Noordsy DL, Brunette MF, et al. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2008;34:61-71.
17. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
18. Suppes T, Webb A, Paul B, et al. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999;156:1164-9.
19. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996;57(Suppl 11):68-71.
20. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
21. Dixon L, Perkins D, Calmes C. Guideline watch (November 2009): Practice guideline for the treatment of patients with schizophrenia, second edition. Arlington (VA): American Psychiatric Association; 2009. Available: www.psychiatryonline.com/content.aspx?aid=501001 (accessed 2010 Mar. 26).
22. Blouin M, Tremblay A, Jalbert ME, et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 2008;16:1780-7.
23. Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009;107:1-12.
24. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007;64:1123-31.
25. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7.
26. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res 2010;117:68-74.
27. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
28. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007;68:1751-62.
29. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry 2005;50(13 Suppl 1):7S-57S.
30. Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-32.
31. National Institute for Health and Clinical Excellence (NICE). NICE Clinical Guideline 82: Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). London (UK): NICE; 2009. Available: www.nice.org.uk/CG082 (accessed 2010 Mar. 26).
32. Hayhurst KP, Brown P, Lewis SW. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study. J Psychopharmacol 2002;16:169-75.
33. Koen L, Magni P, Niehaus DJ, et al. Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry (Johannesbg) 2008;11:287-90.
34. Mallinger JB, Fisher SG, Brown T, et al. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006;57:133-6.
35. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19:542-50.
36. Wheeler A, Humberstone V, Robinson E, et al. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract 2009;15:441-50.
37. Tang YL, Mao PX, Jiang F, et al. Clozapine in China. Pharmacopsychiatry 2008;41:1-9.
38. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13:27-35.
39. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-72.
40. Kapur S, Seeman P. Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
41. Stone JM, Pilowsky LS. Antipsychotic drug action: targets for drug discovery with neurochemical imaging. Expert Rev Neurother 2006; 6:57-64.
42. Gründer G, Hippius H, Carlsson A. The "atypicality" of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009;8:197-202.
43. Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics 2009;6:78-85.
44. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry 2008;13:918-29.